• Dasatinib (BMS-354825): Strategic Leverage in Translational

  2026-05-09

  This thought-leadership article explores how Dasatinib (BMS-354825), a dual Src and Bcr-Abl inhibitor, empowers translational researchers to interrogate the mechanistic drivers of EMT, cancer stemness, and metastatic progression. By integrating mechanistic insights from the SNAI1–PIK3R2/p-EphA2 axis in thymic epithelial tumors (TETs) with experimental protocol recommendations and competitive context, the article provides actionable guidance for advancing kinase-driven malignancy research.

• Polymyxin B Sulfate: Immunological Dimensions in Infection M

  2026-05-08

  Explore how Polymyxin B sulfate advances infection and immunology research, focusing on its nuanced effects on dendritic cell maturation and microbiome-driven immunotherapy responses. This article delivers a distinctive, evidence-based analysis for cutting-edge assay design.

• Alcian Blue & Nuclear Fast Red Staining Kit pH2.5: Workflow

  2026-05-08

  Unlock precise, dual-color detection of mucopolysaccharides and cell nuclei with the Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5. This kit streamlines chondrogenic differentiation assays and small tissue biopsy workflows, offering robust contrast, reproducibility, and simplified protocols for applied histological research.

• Repurposing Lopinavir: Inhibition of MERS-CoV in Cell Cultur

  2026-05-07

  de Wilde et al. screened 348 FDA-approved drugs and identified four, including Lopinavir (ABT-378), as inhibitors of MERS-CoV replication in vitro. This work demonstrates the potential for rapid antiviral deployment by repurposing existing protease inhibitors, with implications for emerging coronavirus outbreaks.

• Dasatinib Monohydrate: Precision Kinase Inhibition in Comple

  2026-05-07

  Explore the scientific depth of Dasatinib Monohydrate in advanced tumor microenvironment modeling, with unique insights into its behavior in assembloid systems and its impact on imatinib-resistant leukemia research. Distinguish your preclinical workflows with this comprehensive analysis.

• SU6656: Bridging Platelet Engineering and Oncology Innovatio

  2026-05-06

  This thought-leadership article explores how SU6656, a selective Src tyrosine kinases inhibitor from APExBIO, catalyzes a dual revolution in translational research: the scalable engineering of functional platelets from hiPSCs and the enhancement of radiotherapy in cancer models. Integrating mechanistic insight with protocol guidance, we dissect both the molecular underpinnings and the broader strategic implications for researchers seeking robust, clinically relevant solutions beyond what conventional product pages offer.

• Crystal Violet Staining Solution: Protocols and Applied Insi

  2026-05-06

  Crystal Violet Staining Solution is a gold standard nuclear staining dye, enabling robust visualization and quantification across colony formation, cell migration, and invasion assays. This guide delivers actionable protocols, troubleshooting strategies, and expert translation of new antibiofilm research to maximize reproducibility and clarity in your workflow.

• NET Formation in CML: Insights into Tyrosine Kinase Inhibito

  2026-05-05

  This study demonstrates that neutrophil extracellular trap (NET) formation is significantly elevated in chronic myeloid leukemia (CML) and is differentially modulated by various tyrosine kinase inhibitors (TKIs). The findings highlight a novel mechanistic link between CML, TKI therapy, and vascular toxicity, providing new directions for research and therapeutic monitoring.

• 3-Methyladenine: Strategic Modulation of Autophagy in Oncolo

  2026-05-05

  This thought-leadership article explores the mechanistic and translational roles of 3-Methyladenine (3-MA) as a selective class III PI3K inhibitor in autophagy research and cancer therapy innovation. We integrate recent advances in ferroptosis escape mechanisms, highlight actionable strategies for experimental design, and position APExBIO’s 3-MA as a gold-standard tool for precision oncology workflows.

• Annexin V-APC/7-AAD Kit: Mechanistic Precision in Apoptosis

  2026-05-04

  Explore how the Annexin V-APC/7-AAD Apoptosis Kit delivers advanced, mechanistically precise apoptosis and necrosis detection. This article uniquely connects phosphatidylserine biology, recent PAD4 research, and practical assay decision-making for next-generation cell death studies.

• Pomalidomide (CC-4047): Protocol Innovations for Myeloma Res

  2026-05-04

  Harness the targeted immunomodulatory power of Pomalidomide (CC-4047) to drive reproducible breakthroughs in hematological malignancy research. This in-depth guide details optimized workflows, key protocol settings, and troubleshooting strategies for maximizing data quality—especially in complex, heterogeneous multiple myeloma models.

• Continuous Rotigotine Delivery in PD and RLS: Clinical Insig

  2026-05-03

  This review details the development of the rotigotine transdermal system, a continuous dopamine D2/D3 receptor agonist therapy, for Parkinson’s disease and restless legs syndrome. Its pharmacokinetic profile, clinical efficacy, and impact on both motor and non-motor symptoms are examined, highlighting translational implications for researchers using dopaminergic pathway modulators.

• MALAT1-miR-125b-STAT3 Axis Regulates PCT in Sepsis: Mechanis

  2026-05-02

  This study elucidates how the long non-coding RNA MALAT1 regulates procalcitonin (PCT) expression in sepsis through its interaction with miR-125b and STAT3. Using patient samples and mechanistic in vitro assays, the findings reveal a potential molecular target for improving sepsis diagnosis and therapy.

• S Tag Peptide: Practical Guide for Fusion Tag Applications

  2026-05-01

  The S Tag Peptide enables efficient recombinant protein detection and purification workflows by improving solubility and providing a robust target for anti-S-Tag antibody detection. It is not suitable for applications requiring direct enzymatic activity or use in ethanol-based buffers. Researchers should use this reagent within its solubility and stability constraints to avoid workflow interruptions.

• Anlotinib Hydrochloride as a Selective VEGFR2 Inhibitor in C

  2026-05-01

  This study delineates the preclinical characterization of anlotinib hydrochloride, highlighting its potency and selectivity as a multi-target tyrosine kinase inhibitor, particularly against VEGFR2. The paper underscores its robust anti-angiogenic activity and superior in vivo efficacy compared to established TKIs, offering valuable insights for translational cancer research.

14799 records 1/987 page Next 12345 下5页 Last page